Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences commercializes FDA-approved sexual and reproductive health products for women’s health. Its product portfolio includes PHEXX® (lactic acid, citric acid and potassium bitartrate), a hormone-free contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, an oral antibiotic for bacterial vaginosis and trichomoniasis.
Company news commonly covers product sales, operating results, commercialization partnerships, distribution agreements and international regulatory activity for PHEXX and SOLOSEC. Updates also include manufacturing and supply arrangements, stockholder votes, capital-market actions and education or advocacy initiatives tied to women’s health communication.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the publication of a manuscript in Advances in Therapy, discussing variability in contraceptive clinical trial designs and their impact on efficacy outcomes. The study highlights challenges in comparing efficacy across non-hormonal and hormonal contraception due to variations in trial protocols. Key findings show that the exclusion of certain menstrual cycles can misrepresent the effectiveness of contraceptives. The paper aims to raise awareness among healthcare providers regarding these nuances, thereby improving contraceptive counseling.
Evofem Biosciences (NASDAQ: EVFM) announced the presentation of seven clinical trial data sets on its products, Phexxi and EVO100, at four medical society meetings in October 2021. Leading the presentations is Dr. Brandi Howard, who highlighted significant interest from healthcare providers. The posters will cover topics including genitourinary symptoms and the effectiveness of the vaginal pH modulator in preventing STIs. Notably, the AMPREVENCE study showcased statistically significant reductions in the risk of chlamydia and gonorrhea infections. The abstracts will be published in relevant medical journals.
Summary not available.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.
Evofem Biosciences (NASDAQ: EVFM) reported a net loss of $33.4 million, improving from $46.2 million in Q1 2021. Phexxi sales surged by 68% to $1.9 million, with a 47% increase in prescriptions and a 52% growth in prescriber base. Operating expenses fell by 6% to $43 million, despite a 17% rise in R&D costs to $8.5 million. A celebrity campaign is set to launch in September 2021 to boost brand awareness. Cash and equivalents stood at $47 million as of June 30, 2021. The company remains on track for the EVOGUARD trial completion by year-end.
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on August 11, 2021, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. Participants can access the event live and via archived presentation at this link. For phone participation, dial (866) 503-5561 (U.S.) or (253) 336-2965, using conference ID 9190716. An audio replay will be available for 24 hours post-call. Evofem focuses on innovative women's health solutions, including its FDA-approved product Phexxi®.
Evofem Biosciences (NASDAQ: EVFM) reported strong growth for its hormone-free contraceptive Phexxi in Q2 2021, dispensing over 14,000 units and involving more than 5,400 healthcare providers. Notably, 60% of new users are aged 18 to 34, with many switching from hormonal methods. CEO Saundra Pelletier highlighted a growing trend among women prioritizing hormone-free options. Detailed metrics will be discussed in the upcoming earnings call in August, further solidifying Phexxi's position in women's reproductive health.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 a.m. ET. The presentation will be available via live webcast and archived for 30 days. The company focuses on developing products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi, launched in September 2020. Evofem is also evaluating the EVO100 candidate for preventing specific STIs in an ongoing Phase 3 clinical trial, EVOGUARD.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET. The presentation will focus on the commercialization of Evofem's hormone-free contraceptive Phexxi®, the Phase 3 clinical trial for EVO100 to prevent chlamydia and gonorrhea in women, and other initiatives. Interested participants can pre-register for the presentation at ldmicrojune2021.mysequire.com.
Evofem Biosciences, Inc. (NASDAQ: EVFM) has successfully closed a public offering of 50 million shares of common stock, raising approximately $46.6 million after expenses. The offering included warrants for an additional 50 million shares, with the underwriter granted a 30-day option for an extra 7.5 million shares and warrants. The proceeds will fund commercialization efforts for Phexxi, ongoing clinical trials for EVO100, and general corporate purposes. The offering was conducted under Evofem's effective shelf registration statement, and all securities were sold by the company.